Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market Following Q3 Earnings and Revenue Guidance Update

Stock Track11-06

Xeris Pharmaceuticals Inc (XERS) saw its stock price plummet 6.79% in pre-market trading on Thursday, following the release of its third-quarter earnings report and an update to its revenue guidance for 2025.

The company reported a net income of $621,000 for the third quarter, with earnings per share of $0. Product revenue for the quarter came in at $74.063 million, slightly below the IBES estimate of $74.2 million. Despite the miss on revenue, Xeris Biopharma posted an operating income of $6.731 million for the quarter, showcasing operational efficiency.

In addition to the Q3 results, Xeris Biopharma Holdings Inc updated its 2025 revenue guidance to a range of $285-$290 million. This updated outlook may have fallen short of previous market expectations, potentially contributing to the significant pre-market decline. Investors appear to be reassessing the company's growth prospects in light of these financial updates, leading to the sharp sell-off in early trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113153563?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113153563","market":"hk","top_or_hot":-1,"title":"Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market Following Q3 Earnings and Revenue Guidance Update","media":"Stock Track","content":"<p>Xeris Pharmaceuticals Inc (XERS) saw its stock price plummet 6.79% in pre-market trading on Thursday, following the release of its third-quarter earnings report and an update to its revenue guidance for 2025.</p>\n\n<p>The company reported a net income of $621,000 for the third quarter, with earnings per share of $0. Product revenue for the quarter came in at $74.063 million, slightly below the IBES estimate of $74.2 million. Despite the miss on revenue, Xeris Biopharma posted an operating income of $6.731 million for the quarter, showcasing operational efficiency.</p>\n\n<p>In addition to the Q3 results, Xeris Biopharma Holdings Inc updated its 2025 revenue guidance to a range of $285-$290 million. This updated outlook may have fallen short of previous market expectations, potentially contributing to the significant pre-market decline. Investors appear to be reassessing the company's growth prospects in light of these financial updates, leading to the sharp sell-off in early trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market Following Q3 Earnings and Revenue Guidance Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market Following Q3 Earnings and Revenue Guidance Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xeris Pharmaceuticals Inc (XERS) saw its stock price plummet 6.79% in pre-market trading on Thursday, following the release of its third-quarter earnings report and an update to its revenue guidance for 2025.</p>\n\n<p>The company reported a net income of $621,000 for the third quarter, with earnings per share of $0. Product revenue for the quarter came in at $74.063 million, slightly below the IBES estimate of $74.2 million. Despite the miss on revenue, Xeris Biopharma posted an operating income of $6.731 million for the quarter, showcasing operational efficiency.</p>\n\n<p>In addition to the Q3 results, Xeris Biopharma Holdings Inc updated its 2025 revenue guidance to a range of $285-$290 million. This updated outlook may have fallen short of previous market expectations, potentially contributing to the significant pre-market decline. Investors appear to be reassessing the company's growth prospects in light of these financial updates, leading to the sharp sell-off in early trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XERS","symbol_name":"Xeris制药","start_time":0,"source_url":"","article_id":"1113153563","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113153563","pubTimestamp":1762430807,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Xeris Pharmaceuticals Inc (XERS) saw its stock price plummet 6.79% in pre-market trading on Thursday, following the release of its third-quarter earnings report and an update to its revenue guidance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XERS":"Xeris制药"},"translate_title":"个股追踪|Xeris Pharmaceuticals在Q3盈利和营收指引更新后盘前暴跌6.79%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":1},"content_text":"Xeris Pharmaceuticals Inc (XERS) saw its stock price plummet 6.79% in pre-market trading on Thursday, following the release of its third-quarter earnings report and an update to its revenue guidance for 2025.\nThe company reported a net income of $621,000 for the third quarter, with earnings per share of $0. Product revenue for the quarter came in at $74.063 million, slightly below the IBES estimate of $74.2 million. Despite the miss on revenue, Xeris Biopharma posted an operating income of $6.731 million for the quarter, showcasing operational efficiency.\nIn addition to the Q3 results, Xeris Biopharma Holdings Inc updated its 2025 revenue guidance to a range of $285-$290 million. This updated outlook may have fallen short of previous market expectations, potentially contributing to the significant pre-market decline. Investors appear to be reassessing the company's growth prospects in light of these financial updates, leading to the sharp sell-off in early trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113153563","isCrawlerRequest":true}